Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion
PTA17333
Approved small_molecule active
Quick answer
Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion for Glycogen storage disease type II is a Approved program (small_molecule) at Sanofi Winthrop Industrie with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Winthrop Industrie
- Indication
- Glycogen storage disease type II
- Phase
- Approved
- Modality
- small_molecule
- Status
- active